Continuous prophylactic antibiotics in moderate COPD results in which outcome?

Continuous prophylactic antibiotics in moderate COPD results in which outcome?

• A. No change
• B. Increased hospitalizations
• C. Clinically significant reduction in COPD exacerbations
• D. Worsened lung function

Answer: (C)

Long-term prophylactic antibiotics, especially macrolides like azithromycin, are used in COPD patients who have frequent exacerbations despite optimal inhaled therapy. The major benefit seen is a clinically meaningful reduction in the rate of COPD exacerbations. This decrease in exacerbations often leads to fewer hospitalizations and improved quality of life, even though baseline lung function (FEV1) typically does not improve. It’s important to balance the benefit with risks such as antibiotic resistance and potential side effects (e.g., hearing changes, QT prolongation).

Long-term prophylactic antibiotics, especially macrolides like azithromycin, are used in COPD patients who have frequent exacerbations despite optimal inhaled therapy. The major benefit seen is a clinically meaningful reduction in the rate of COPD exacerbations. This decrease in exacerbations often leads to fewer hospitalizations and improved quality of life, even though baseline lung function (FEV1) typically does not improve. It’s important to balance the benefit with risks such as antibiotic resistance and potential side effects (e.g., hearing changes, QT prolongation).